Guselkumab yields ‘significant inhibition’ of psoriatic arthritis structural damage

Guselkumab, whether administered every 4 or 8 weeks, demonstrates “significant inhibition” of structural damage in patients with active psoriatic arthritis, according to data presented at the EULAR 2025 Congress.“The objective of this phase 3b study is to more closely evaluate the ability of both Q4- and Q8-week dosing to inhibit structural damage progression,” Philip J.